SCAI statement on ad hoc versus the separate performance of diagnostic cardiac catheteriza- tion and coronary intervention. Catheter Cardiovasc Interv. 2004;63: 444 51. 312. Agard A, Herlitz J, Hermeren G. Obtaining informed consent from patients in the early phase of acute myocardial infarction: physicians experiences and attitudes. Heart. 2004;90:208 10. 313. Foex BA. Is informed consent possible in acute myocardial infarction? Heart. 2004;90:1237 8. 314. Williams BF, French JK, White HD. Informed consent during the clinical emergency of acute myocardial infarction (HERO-2 consent substudy): a prospective observational study. Lancet. 2003;361:918 22. 315. Ritchie JL, Wolk MJ, Hirshfeld JW Jr, et al. Task force 4: appropriate clinical care and issues of self-referral. J Am Coll Cardiol. 2004;44: 1740 6. 316. Hirshfeld JW Jr, Balter S, Brinker JA, et al. ACCF/AHA/HRS/SCAI clinical competence statement on physician knowledge to optimize patient safety and image quality in fluoroscopically guided invasive cardiovascular procedures. A report of the American College of Car- diology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training. Circu- lation. 2005;111:511 32. 317. Chambers C, Fetterly K, Holzer R, et al. Radiation safety program for the cardiac catheterization laboratory. Catheter Cardiovasc Interv. 2011; 77:546 56. 318. Deleted in proof. 319. Deleted in proof. 320. Krasuski RA, Beard BM, Geoghagan JD, et al. Optimal timing of hydration to erase contrast-associated nephropathy: the OTHER CAN study. J Invasive Cardiol. 2003;15:699 702. 321. Taylor AJ, Hotchkiss D, Morse RW, et al. PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to- moderate renal dysfunction. Chest. 1998;114:1570 4. 322. Adolph E, Holdt-Lehmann B, Chatterjee T, et al. Renal Insufficiency Following Radiocontrast Exposure Trial (REINFORCE): a randomized comparison of sodium bicarbonate versus sodium chlo-ride hydration for the prevention of contrast-induced nephropathy. Coron Artery Dis. 2008;19:413 9. 323. Brar SS, Shen AY, Jorgensen MB, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA. 2008;300:1038 46. 324. Brar SS, Hiremath S, Dangas G, et al. Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4:1584 92. 325. Briguori C, Airoldi F, D Andrea D, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized com- parison of 3 preventive strategies. Circulation. 2007;115:1211 7. 326. From AM, Bartholmai BJ, Williams AW, et al. Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a ret- rospective cohort study of 7977 patients at Mayo Clinic. Clin J Am Soc Nephrol. 2008;3:10 8. 327. Hoste EA, De Waele JJ, Gevaert SA, et al. Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis. Nephrol Dial Transplant. 2010;25:747 58. 328. Kelly AM, Dwamena B, Cronin P, et al. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med. 2008;148:284 94. 329. Maioli M, Toso A, Leoncini M, et al. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol. 2008;52:599 604. 330. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291:2328 34. 331. Pannu N, Manns B, Lee H, et al. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int. 2004;65: 1366 74. 332. Vaitkus PT, Brar C. N-acetylcysteine in the prevention of contrast- induced nephropathy: publication bias perpetuated by meta-analyses. Am Heart J. 2007;153:275 80. 333. Deleted in proof. 334. Heinrich MC, Haberle L, Muller V, et al. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta- analysis of randomized controlled trials. Radiology. 2009;250:68 86. 335. Kuhn MJ, Chen N, Sahani DV, et al. The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure. AJR Am J Roentgenol. 2008;191: 151 7. 336. Reed M, Meier P, Tamhane UU, et al. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials. J Am Coll Cardiol Intv. 2009;2:645 54. 337. Rudnick MR, Davidson C, Laskey W, et al. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insuffi- ciency (VALOR) Trial. Am Heart J. 2008;156:776 82. 338. Solomon RJ, Natarajan MK, Doucet S, et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007;115:3189 96. 339. Thomsen HS, Morcos SK, Erley CM, et al. The ACTIVE Trial: com- parison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. Invest Radiol. 2008;43:170 8. 340. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circu- lation. 2011;123:2022 60. 341. Goss JE, Chambers CE, Heupler FA Jr. Systemic anaphylactoid reactions to iodinated contrast media during cardiac catheterization procedures: guidelines for prevention, diagnosis, and treatment. Labo- ratory Performance Standards Committee of the Society for Cardiac Angiography and Interventions. Cathet Cardiovasc Diagn. 1995;34: 99 104. 342. Hubbard CR, Blankenship JC, Scott TD, et al. Emergency pretreatment for contrast allergy before direct percutaneous coronary intervention for ST-elevation myocardial infarction. Am J Cardiol. 2008;102:1469 72. 343. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383 9. 344. MRC/BHF Heart Protection Study of cholesterol lowering with simva- statin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7 22. 345. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495 504. 346. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001 9. 347. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285: 1711 8. 348. Ray KK, Cannon CP. The potential relevance of the multiple lipid- independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol. 2005;46:1425 33. 349. Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation. 2001;103: 961 6. 350. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294:3108 16. 351. Aversano T, Aversano LT, Passamani E, et al. Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a ran- domized controlled trial. JAMA. 2002;287:1943 51. 352. Dehmer GJ, Blankenship J, Wharton TP Jr, et al. The current status and future direction of percutaneous coronary intervention without on-site surgical backup: an expert consensus document from the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2007;69:471 8. 353. Melberg T, Nilsen DW, Larsen AI, et al. Nonemergent coronary angio- plasty without on-site surgical backup: a randomized study evaluating outcomes in low-risk patients. Am Heart J. 2006;152:888 95. 354. Singh PP, Singh M, Bedi US, et al. Outcomes of nonemergent percu- taneous coronary intervention with and without on-site surgical backup: a meta-analysis. Am J Ther. 2011;18:e22 8. 355. Nallamothu BK, Wang Y, Magid DJ, et al. Relation between hospital specialization with primary percutaneous coronary intervention and clinical outcomes in ST-segment elevation myocardial infarction: National Registry of Myocardial Infarction-4 analysis. Circulation. 2006;113:222 9. 356. Brueck M, Bandorski D, Kramer W, et al. A randomized comparison of transradial versus transfemoral approach for coronary angiography and angioplasty. J Am Coll Cardiol Intv. 2009;2:1047 54. 357. Jaffe R, Hong T, Sharieff W, et al. Comparison of radial versus femoral approach for percutaneous coronary interventions in octogenarians. Catheter Cardiovasc Interv. 2007;69:815 20. 358. Louvard Y, Benamer H, Garot P, et al. Comparison of transradial and transfemoral approaches for coronary angiography and angioplasty in octogenarians (the OCTOPLUS study). Am J Cardiol. 2004;94: 1177 80. 359. Pristipino C, Trani C, Nazzaro MS, et al. Major improvement of per- cutaneous cardiovascular procedure outcomes with radial artery cath- eterisation: results from the PREVAIL study. Heart. 2009;95:476 82. 360. Rao SV, Ou FS, Wang TY, et al. Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. J Am Coll Cardiol Intv. 2008;1:379 86. 361. Hamon M, Rasmussen LH, Manoukian SV, et al. Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial. Euro- Intervention. 2009;5:115 20. 362. Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet. 2011;377:1409 20. 363. Vavalle JP, Rao SV. The association between the transradial approach for percutaneous coronary interventions and bleeding. J Invasive Cardiol. 2009;21:21A 4A. 364. Bavry AA, Kumbhani DJ, Rassi AN, et al. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol. 2006;48:1319 25. 365. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879 87. 366. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:708 15. 367. Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009;360: 2165 75. 368. Valgimigli M, Dawkins K, Macaya C, et al. Impact of stable versus unstable coronary artery disease on 1-year outcome in elective patients undergoing multivessel revascularization with sirolimuseluting stents: a subanalysis of the ARTS II trial. J Am Coll Cardiol. 2007;49:431 41. 369. Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333:1091. 370. Pieper KS, Gore JM, Fitzgerald G, et al. Validity of a risk-prediction tool for hospital mortality: the Global Registry of Acute Coronary Events. Am Heart J. 2009;157:1097 105. 371. Damman P, Hirsch A, Windhausen F, et al. 5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable Levine et al 2011 ACCF/AHA/SCAI PCI Guideline e629 coronary Syndromes) trial: a randomized comparison of an early invasive versus selective invasive management in patients with non-ST- segment elevation acute coronary syndrome. J Am Coll Cardiol. 2010; 55:858 64. 372. Fox KA, Poole-Wilson P, Clayton TC, et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet. 2005; 366:914 20. 373. Guagliumi G, Stone GW, Cox DA, et al. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarc- tion: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 2004;110:1598 604. 374. Lagerqvist B, Husted S, Kontny F, et al. 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. Lancet. 2006;368:998 1004. 375. Montalescot G, Cayla G, Collet JP, et al. Immediate vs delayed inter- vention for acute coronary syndromes: a randomized clinical trial. JAMA. 2009;302:947 54. 376. Neumann FJ, Kastrati A, Pogatsa-Murray G, et al. Evaluation of pro- longed antithrombotic pretreatment ( cooling-off strategy) before inter- vention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA. 2003;290:1593 9. 377. Riezebos RK, Ronner E, Ter BE, et al. Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syn- dromes. Heart. 2009;95:807 12. 378. Yan AT, Yan RT, Tan M, et al. In-hospital revascularization and one-year outcome of acute coronary syndrome patients stratified by the GRACE risk score. Am J Cardiol. 2005;96:913 6. 379. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intrave- nous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13 20. 380. Zijlstra F, de Boer MJ, Hoorntje JC, et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med. 1993;328:680 4. 381. Keeley EC, Grines CL. Primary coronary intervention for acute myo- cardial infarction. JAMA. 2004;291:736 9. 382. Keeley EC, Hillis LD. Primary PCI for myocardial infarction with ST-segment elevation. N Engl J Med. 2007;356:47 54. 383. Wu AH, Parsons L, Every NR, et al. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocar-dial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol. 2002;40:1389 94. 384. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coro- naries for Cardiogenic Shock. N Engl J Med. 1999;341:625 34. 385. Gershlick AH, Stephens-Lloyd A, Hughes S, et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med. 2005;353:2758 68. 386. Wijeysundera HC, Vijayaraghavan R, Nallamothu BK, et al. Rescue angioplasty or repeat fibrinolysis after failed fibrinolytic therapy for ST-segment myocardial infarction: a meta-analysis of randomized trials. J Am Coll Cardiol. 2007;49:422 30. 387. Bohmer E, Hoffmann P, Abdelnoor M, et al. Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction). J Am Coll Cardiol. 2010;55:102 10. 388. Di Mario C, Dudek D, Piscione F, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocar-dial Infarction (CARESS-in-AMI): an open, prospective, randomised, mul- ticentre trial. Lancet. 2008;371:559 68. 389. Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, et al. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided con- servative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet. 2004;364: 1045 53. 390. Borgia F, Goodman SG, Halvorsen S, et al. Early routine percutaneous coronary intervention after fibrinolysis vs standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. Eur Heart J. 2010;31:2156 69. 391. Cantor WJ, Fitchett D, Borgundvaag B, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med. 2009; 360:2705 18. 392. Bates ER. Revisiting reperfusion therapy in inferior myocardial infarction. J Am Coll Cardiol. 1997;30:334 42. 393. White HD. Systems of care: need for hub-and-spoke systems for both primary and systematic percutaneous coronary intervention after fibri- nolysis. Circulation. 2008;118:219 22. 394. Lambert L, Brown K, Segal E, et al. Association between timeliness of reperfusion therapy and clinical outcomes in ST-elevation myocardial infarction. JAMA. 2010;303:2148 55. 395. Terkelsen CJ, Sorensen JT, Maeng M, et al. System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA. 2010;304:763 71. 396. Aguirre FV, Varghese JJ, Kelley MP, et al. Rural interhospital transfer of ST-elevation myocardial infarction patients for percutaneous coronary revascularization: the Stat Heart Program. Circulation. 2008; 117:1145 52. 397. Blankenship JC, Scott TD, Skelding KA, et al. Door-to-balloon times under 90 min can be routinely achieved for patients transferred for ST-segment elevation myocardial infarction percutaneous coronary intervention in a rural setting. J Am Coll Cardiol. 2011;57:272 9. 398. Henry TD, Sharkey SW, Burke MN, et al. A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction. Circulation. 2007;116:721 8. 399. Zahn R, Schuster S, Schiele R, et al., Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) Study Group. Comparison of primary angioplasty with conservative therapy in patients with acute myocardial infarction and contraindications for thrombolytic therapy. Catheter Cardiovasc Interv. 1999;46:127 33. 400. Grzybowski M, Clements EA, Parsons L, et al. Mortality benefit of immediate revascularization of acute ST-segment elevation myocar-dial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis. JAMA. 2003;290:1891 8. 401. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: col- laborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343: 311 22. 402. Schomig A, Mehilli J, Antoniucci D, et al. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA. 2005;293: 2865 72. 403. Gierlotka M, Gasior M, Wilczek K, et al. Reperfusion by primary percutaneous coronary intervention in patients with ST-segment ele- vation myocardial infarction within 12 to 24 hours of the onset of symptoms (from a prospective national observational study [PLACS]). Am J Cardiol. 2011;107:501 8. 404. Toma M, Buller CE, Westerhout CM, et al. Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. Eur Heart J. 2010;31:1701 7. 405. Widimsky P, Holmes DR Jr. How to treat patients with ST-elevation acute myocardial infarction and multi-vessel disease? Eur Heart J. 2011; 32:396 403. 406. Politi L, Sgura F, Rossi R, et al. A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarc- tion: major adverse cardiac events during long-term follow-up. Heart. 2010;96:662 7. 407. Vlaar PJ, Mahmoud KD, Holmes DR Jr, et al. Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multi- vessel disease in patients presenting with ST-segment elevation myo- cardial infarction: a pairwise and network meta-analysis. J Am Coll Cardiol. 2011;58:692 703. 408. Kornowski R, Mehran R, Dangas G, et al. Prognostic impact of staged versus one-time multivessel percutaneous interventions in acute myo- cardial infarction: analysis from the HORIZONS-AMI trial. J Am Coll Cardiol. 2011;58:704 11. 409. Rathore SS, Curtis JP, Chen J, et al. Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myo- cardial infarction: national cohort study. BMJ. 2009;338:b1807. 410. Erne P, Schoenenberger AW, Burckhardt D, et al. Effects of percuta- neous coronary interventions in silent ischemia after myocar-dial infarc- tion: the SWISSI II randomized controlled trial. JAMA. 2007;297: 1985 91. 411. Madsen JK, Grande P, Saunamaki K, et al. Danish multicenter ran- domized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction. Circulation. 1997;96:748 55. 412. Hannan EL, Samadashvili Z, Walford G, et al. Culprit vessel percuta- neous coronary intervention versus multivessel and staged percutaneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel disease. J Am Coll Cardiol Intv. 2010;3:22 31. 413. Stenestrand U, Wallentin L. Early revascularisation and 1-year survival in 14-day survivors of acute myocardial infarction: a prospective cohort study. Lancet. 2002;359:1805 11. 414. Alter DA, Tu JV, Austin PC, et al. Waiting times, revascularization modality, and outcomes after acute myocardial infarction at hospitals with and without on-site revascularization facilities in Canada. J Am Coll Cardiol. 2003;42:410 9. 415. Zeymer U, Uebis R, Vogt A, et al. Randomized comparison of percu- taneous transluminal coronary angioplasty and medical therapy in stable survivors of acute myocardial infarction with single vessel disease: a study of the Arbeitsgemeinschaft Leitende Kardiologische Kranken- hausarzte. Circulation. 2003;108:1324 8. 416. Gupta M, Chang WC, Van de Werf F, et al. International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2. Eur Heart J. 2003;24:1640 50. 417. Gibson CM, Karha J, Murphy SA, et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic adminis- tration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol. 2003;42:7 16. 418. Ioannidis JP, Katritsis DG. Percutaneous coronary intervention for late reperfusion after myocardial infarction in stable patients. Am Heart J. 2007;154:1065 71. 419. Steg PG, Thuaire C, Himbert D, et al. DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction. Eur Heart J. 2004;25:2187 94. 420. Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006; 355:2395 407. 421. Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. JAMA. 2001;285:190 2. 422. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA. 2006;295:2511 5. 423. Urban P, Stauffer JC, Bleed D, et al. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock (S)MASH. Eur Heart J. 1999;20:1030 8. 424. Sanborn TA, Sleeper LA, Bates ER, et al. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol. 2000; 36:1123 9. 425. Chen EW, Canto JG, Parsons LS, et al. Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock. Circulation. 2003;108:951 7. 426. Barron HV, Every NR, Parsons LS, et al. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. Am Heart J. 2001;141:933 9. 427. Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation. 2008;117:686 97. 428. Antoniucci D, Valenti R, Migliorini A, et al. Comparison of impact of emergency percutaneous revascularization on outcome of patients or 75 to those 75 years of age with acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol. 2003;91:1458 61. 429. Dauerman HL, Ryan TJ Jr, Piper WD, et al. Outcomes of percutaneous coronary intervention among elderly patients in cardiogenic shock: a multicenter, decade-long experience. J Invasive Cardiol. 2003;15: 380 4. 430. Dzavik V, Sleeper LA, Cocke TP, et al. Early revascularization is associated with improved survival in elderly patients with acute myo- cardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry. Eur Heart J. 2003;24:828 37. 431. Prasad A, Lennon RJ, Rihal CS, et al. Outcomes of elderly patients with cardiogenic shock treated with early percutaneous revascularization. Am Heart J. 2004;147:1066 70. 432. Babaev A, Every NR, Frederick P. Trends in revascularization and mortality in patients with cardiogeneic shock complicating acute myo- cardial infarction. Circulation. 2002;106 Suppl II:364. Abstract. 433. Thiele H, Allam B, Chatellier G, et al. Shock in acute myocardial infarction: the Cape Horn for trials? Eur Heart J. 2010;31:1828 35. 434. Sjauw KD, Engstrom AE, Vis MM, et al. A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myo- cardial infarction: should we change the guidelines? Eur Heart J. 2009; 30:459 68. 435. Bates ER. Percutaneous coronary intervention for cardiogenic shock. In: Hochman JS, Ohman EM, editors. Cardiogenic Shock. Hoboken, NJ: Wiley-Blackwell; 2009:220 39. 436. Antoniucci D, Valenti R, Santoro GM, et al. Systematic direct angio- plasty and stent-supported direct angioplasty therapy for cardiogenic shock complicating acute myocardial infarction: in-hospital and long-term survival. J Am Coll Cardiol. 1998;31:294 300. 437. Chan AW, Chew DP, Bhatt DL, et al. Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock compli- cating acute myocardial infarction. Am J Cardiol. 2002;89:132 6. 438. Huang R, Sacks J, Thai H, et al. Impact of stents and abciximab on survival from cardiogenic shock treated with percutaneous coronary intervention. Catheter Cardiovasc Interv. 2005;65:25 33. 439. Yip HK, Wu CJ, Chang HW, et al. Comparison of impact of primary percutaneous transluminal coronary angioplasty and primary stenting on short-term mortality in patients with cardiogenic shock and evaluation of prognostic determinants. Am J Cardiol. 2001;87:1184 8. 440. Giri S, Mitchel J, Azar RR, et al. Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol. 2002;89:126 31. 441. Mehta RH, Lopes RD, Ballotta A, et al. Percutaneous coronary inter- vention or coronary artery bypass surgery for cardiogenic shock and multivessel coronary artery disease? Am Heart J. 2010;159:141 7. 442. Berger PB, Bell MR, Hasdai D, et al. Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. Circu- lation. 1999;99:248 53. 443. Cruden NL, Harding SA, Flapan AD, et al. Previous coronary stent implantation and cardiac events in patients undergoing noncardiac surgery. Circ Cardiovasc Interv. 2010;3:236 42. 444. Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. Circulation. 2009;120:e169 276. 445. Kaluza GL, Joseph J, Lee Jr, et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol. 2000;35: 1288 94. 446. Reddy PR, Vaitkus PT. Risks of noncardiac surgery after coronary stenting. Am J Cardiol. 2005;95:755 7. 447. Sharma AK, Ajani AE, Hamwi SM, et al. Major noncardiac surgery following coronary stenting: when is it safe to operate? Catheter Car- diovasc Interv. 2004;63:141 5. 448. Wilson SH, Fasseas P, Orford JL, et al. Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol. 2003;42:234 40. 449. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascular- ization before elective major vascular surgery. N Engl J Med. 2004;351: 2795 804. 450. Schouten O, van Kuijk JP, Flu WJ, et al. Long-term outcome of pro- phylactic coronary revascularization in cardiac high-risk patients undergoing major vascular surgery (from the randomized DECREASE-V Pilot Study). Am J Cardiol. 2009;103:897 901. 451. Kaluza GL, Joseph J, Lee Jr, et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol. 2000;35: 1288 94. 452. Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007; 297:2001 9. 453. Mauri L, Silbaugh TS, Garg P, et al. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med. 2008;359:1330 42. Levine et al 2011 ACCF/AHA/SCAI PCI Guideline e631 453a.Mehilli J, Pache J, Abdel-Wahab M, et al. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet. 2011: published online before print August 28, 2011, doi:10.1016/S0140-6736(11)61255-5. 454. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315 23. 455. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109:1942 7. 456. Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med. 2009; 360:1946 59. 457. Pan XH, Chen YX, Xiang MX, et al. A meta-analysis of randomized trials on clinical outcomes of paclitaxel-eluting stents versus bare-metal stents in ST-segment elevation myocardial infarction patients. J Zhejiang Univ Sci B. 2010;11:754 61. 458. Hao PP, Chen YG, Wang XL, et al. Efficacy and safety of drug-eluting stents in patients with acute ST-segment-elevation myocardial infarc- tion: a meta-analysis of randomized controlled trials. Tex Heart Inst J. 2010;37:516 24. 459. Suh HS, Song HJ, Choi JE, et al. Drug-eluting stents versus bare-metal stents in acute myocardial infarction: a systematic review and meta- analysis. Int J Technol Assess Health Care. 2011;27:11 22. 460. Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol. 2006;98:352 6. 461. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Cir- culation. 2006;113:2803 9. 462. Nasser M, Kapeliovich M, Markiewicz W. Late thrombosis of sirolimus- eluting stents following noncardiac surgery. Catheter Cardiovasc Interv. 2005;65:516 9. 463. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496 501. 464. Serruys PW, De Jaegere P, Kiemeneij F, et al. A comparison of balloon- expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994; 331:489 95. 465. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356: 998 1008. 466. Stone GW, Midei M, Newman W, et al. Comparison of an everolimus- eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008;299:1903 13. 467. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362:1663 74. 468. Stone GW, Midei M, Newman W, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation. 2009;119:680 6. 469. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193 202. 470. Cohen DJ, Bakhai A, Shi C, et al. Cost-effectiveness of sirolimuseluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation. 2004;110:508 14. 471. Boyden TF, Nallamothu BK, Moscucci M, et al. Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus. Am J Cardiol. 2007;99:1399 402. 472. Stettler C, Allemann S, Wandel S, et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta- analysis. BMJ. 2008;337:a1331. 473. Chieffo A, Stankovic G, Bonizzoni E, et al. Early and mid-term results of drug-eluting stent implantation in unprotected left main. Circulation. 2005;111:791 5. 474. Erglis A, Narbute I, Kumsars I, et al. A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unpro- tected left main coronary artery stenosis. J Am Coll Cardiol. 2007;50: 491 7. 475. Price MJ, Cristea E, Sawhney N, et al. Serial angiographic follow-up of sirolimus-eluting stents for unprotected left main coronary artery revas- cularization. J Am Coll Cardiol. 2006;47:871 7. 476. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circu- lation. 2001;103:1967 71. 477. Singh M, Gersh BJ, McClelland RL, et al. Predictive factors for ische- mic target vessel revascularization in the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. J Am Coll Cardiol. 2005; 45:198 203. 478. Schulz S, Schuster T, Mehilli J, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J. 2009;30:2714 21. 479. Nordmann AJ, Hengstler P, Harr T, et al. Clinical outcomes of primary stenting versus balloon angioplasty in patients with myocar-dial infarc- tion: a meta-analysis of randomized controlled trials. Am J Med. 2004; 116:253 62. 480. Gao F, Zhou YJ, Wang ZJ, et al. Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation. Int J Cardiol. 2011; 148:96 101. 481. Levine GN, Gomes AS, Arai AE, et al. Safety of magnetic resonance imaging in patients with cardiovascular devices: an American Heart Association scientific statement from the Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology, and the Council on Cardiovascular Radiology and Intervention. Circu- lation. 2007;116:2878 91. 482. Hundley WG, Bluemke DA, Finn JP, et al. ACCF/ACR/AHA/ NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance. Circulation. 2010;121:2462 508. 483. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endo- carditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116:1736 54. 484. Hamilos M, Muller O, Cuisset T, et al. Long-term clinical outcome after fractional flow reserve-guided treatment in patients with angio- graphically equivocal left main coronary artery stenosis. Circulation. 2009;120:1505 12. 485. Pijls NH, van Schaardenburgh P, Manoharan G, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol. 2007;49:2105 11. 486. Pijls NH, Fearon WF, Tonino PA, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Eval- uation) study. J Am Coll Cardiol. 2010;56:177 84. 487. Kern MJ, Samady H. Current concepts of integrated coronary phys- iology in the catheterization laboratory. J Am Coll Cardiol. 2010;55: 173 85. 488. Nam CW, Yoon HJ, Cho YK, et al. Outcomes of percutaneous coronary intervention in intermediate coronary artery disease: fractional flow reserve-guided versus intravascular ultrasound-guided. J Am Coll Cardiol Intv. 2010;3:812 7. 489. Briguori C, Anzuini A, Airoldi F, et al. Intravascular ultrasound criteria for the assessment of the functional significance of intermediate coronary artery stenoses and comparison with fractional flow reserve. Am J Cardiol. 2001;87:136 41. 490. Fassa AA, Wagatsuma K, Higano ST, et al. Intravascular ultrasound- guided treatment for angiographically indeterminate left main coronary artery disease: a long-term follow-up study. J Am Coll Cardiol. 2005; 45:204 11. 491. Kang SJ, Lee JY, Ahn JM, et al. Validation of intravascular ultrasound- derived parameters with fractional flow reserve for assessment of coronary stenosis severity. Circ Cardiovasc Interv. 2011;4:65 71. 492. Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29:914 56. 493. Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol. 2005;45:1532 7. 494. Kapadia SR, Nissen SE, Ziada KM, et al. Development of transplan- tation vasculopathy and progression of donor-transmitted atherosclero- sis: comparison by serial intravascular ultrasound imaging. Circulation. 1998;98:2672 8. 495. Dangas GD, Claessen BE, Caixeta A, et al. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56:1897 907. 496. Takagi A, Tsurumi Y, Ishii Y, et al. Clinical potential of intravascular ultrasound for physiological assessment of coronary stenosis: rela- tionship between quantitative ultrasound tomography and pressure- derived fractional flow reserve. Circulation. 1999;100:250 5. 497. Magni V, Chieffo A, Colombo A. Evaluation of intermediate coronary stenosis with intravascular ultrasound and fractional flow reserve: its use and abuse. Catheter Cardiovasc Interv. 2009;73:441 8. 498. Park SJ, Kim YH, Park DW, et al. Impact of intravascular ultrasound guidance on long-term mortality in stenting for unprotected left main coronary artery stenosis. Circ Cardiovasc Interv. 2009;2:167 77. 499. Lee CW, Kang SJ, Park DW, et al. Intravascular ultrasound findings in patients with very late stent thrombosis after either drug-eluting or bare-metal stent implantation. J Am Coll Cardiol. 2010;55:1936 42. 500. Okabe T, Mintz GS, Lee SY, et al. Five-year outcomes of moderate or ambiguous left main coronary artery disease and the intravascular ultrasound predictors of events. J Invasive Cardiol. 2008;20:635 9. 501. Parikh, SV, Selzer, F, Abbott, JD, Marroquin, OC. No long term clinical effect of IVUS guided PCI: results from the NHLBI dynamic registry. Circulation. 2009;120 Abstract. 502. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascu- larization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2010;31:2501 55. 503. Hodgson JM. If you want to stent do intravascular ultrasound! J Am Coll Cardiol Intv. 2010;3:818 20. 504. Bezerra HG, Costa MA, Guagliumi G, et al. Intracoronary optical coherence tomography: a comprehensive review clinical and research applications. J Am Coll Cardiol Intv. 2009;2:1035 46. 505. Prati F, Regar E, Mintz GS, et al. Expert review document on meth- odology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atheroscle- rosis. Eur Heart J. 2010;31:401 15. 506. Barlis P, Gonzalo N, Di Mario C, et al. A multicentre evaluation of the safety of intracoronary optical coherence tomography. EuroIntervention. 2009;5:90 5. 507. Yamaguchi T, Terashima M, Akasaka T, et al. Safety and feasibility of an intravascular optical coherence tomography image wire system in the clinical setting. Am J Cardiol. 2008;101:562 7. 508. Mintz GS, Nissen SE, Anderson WD, et al. American College of Cardiology clinical expert consensus document on standards for acqui- sition, measurement and reporting of intravascular ultrasound studies (IVUS). A report of the American College of Cardiology task force on clinical expert consensus documents. J Am Coll Cardiol. 2001;37: 1478 92. 509. Fujii K, Kawasaki D, Masutani M, et al. OCT assessment of thin-cap fibroatheroma distribution in native coronary arteries. J Am Coll Cardiol Img. 2010;3:168 75. 510. Mizukoshi M, Imanishi T, Tanaka A, et al. Clinical classification and plaque morphology determined by optical coherence tomography in unstable angina pectoris. Am J Cardiol. 2010;106:323 8. 511. Chen BX, Ma FY, Luo W, et al. Neointimal coverage of bare-metal and sirolimus-eluting stents evaluated with optical coherence tomography. Heart. 2008;94:566 70. 512. Kubo T, Imanishi T, Kitabata H, et al. Comparison of vascular response after sirolimus-eluting stent implantation between patients with unstable and stable angina pectoris: a serial optical coherence tomography study. J Am Coll Cardiol Img. 2008;1:475 84. 513. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus- eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373:897 910. 514. Moussa I, Di Mario C, Moses J, et al. Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results. Circulation. 1997;96:128 36. 515. Vaquerizo B, Serra A, Miranda F, et al. Aggressive plaque modification with rotational atherectomy and/or cutting balloon before drug-eluting stent implantation for the treatment of calcified coronary lesions. J Interv Cardiol. 2010;23:240 8. 516. Bittl JA, Chew DP, Topol EJ, et al. Meta-analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty. J Am Coll Cardiol. 2004;43:936 42. 517. Mauri L, Reisman M, Buchbinder M, et al. Comparison of rotational atherectomy with conventional balloon angioplasty in the prevention of restenosis of small coronary arteries: results of the Dilatation vs Ablation Revascularization Trial Targeting Restenosis (DART). Am Heart J. 2003;145:847 54. 518. Reifart N, Vandormael M, Krajcar M, et al. Randomized comparison of angioplasty of complex coronary lesions at a single center. Excimer Laser, Rotational Atherectomy, and Balloon Angioplasty Comparison (ERBAC) Study. Circulation. 1997;96:91 8. 519. vom Dahl J, Dietz U, Haager PK, et al. Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the angioplasty versus rotational atherectomy for treatment of diffuse in-stent restenosis trial (ARTIST). Circulation. 2002;105:583 8. 520. Brogan WCI, Popma JJ, Pichard AD, et al. Rotational coronary atherectomy after unsuccessful coronary balloon angioplasty. Am J Cardiol. 1993;71:794 8. 521. Kobayashi Y, Teirstein P, Linnemeier T, et al. Rotational atherectomy (stentablation) in a lesion with stent underexpansion due to heavily calcified plaque. Catheter Cardiovasc Interv. 2001;52:208 11. 522. Sardella G, Mancone M, Bucciarelli-Ducci C, et al. Thrombus aspiration during primary percutaneous coronary intervention improves myo- cardial reperfusion and reduces infarct size: the EXPIRA (throm- bectomy with export catheter in infarct-related artery during primary percutaneous coronary intervention) prospective, randomized trial. J Am Coll Cardiol. 2009;53:309 15. 523. Vlaar PJ, Svilaas T, van der Horst IC, et al. Cardiac death and rein- farction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet. 2008;371:1915 20. 524. Bavry AA, Kumbhani DJ, Bhatt DL. Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a com- prehensive meta-analysis of randomized trials. Eur Heart J. 2008;29: 2989 3001. 525. Ali A, Cox D, Dib N, et al. Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction: 30-day results from a multicenter randomized study. J Am Coll Cardiol. 2006;48:244 52. 526. Migliorini A, Stabile A, Rodriguez AE, et al. Comparison of AngioJet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute myocardial infarction: the JETSTENT trial. J Am Coll Cardiol. 2010;56:1298 306. 527. Noble S, Bilodeau L. High energy excimer laser to treat coronary in-stent restenosis in an underexpanded stent. Catheter Cardiovasc Interv. 2008;71:803 7. 528. Stone GW, de Marchena E, Dageforde D, et al., The Laser Angioplasty Versus Angioplasty (LAVA) Trial Investigators. Prospective, ran- domized, multicenter comparison of laser-facilitated balloon angioplasty versus stand-alone balloon angioplasty in patients with obstructive coronary artery disease. J Am Coll Cardiol. 1997;30:1714 21. 529. Albiero R, Silber S, Di Mario C, et al. Cutting balloon versus conven- tional balloon angioplasty for the treatment of in-stent restenosis: results of the restenosis cutting balloon evaluation trial (RESCUT). J Am Coll Cardiol. 2004;43:943 9. 530. Mauri L, Bonan R, Weiner BH, et al. Cutting balloon angioplasty for the prevention of restenosis: results of the Cutting Balloon Global Ran- domized Trial. Am J Cardiol. 2002;90:1079 83. 531. de Ribamar CJ Jr, Mintz GS, Carlier SG, et al. Nonrandomized com- parison of coronary stenting under intravascular ultrasound guidance of direct stenting without predilation versus conventional predilation with a semi-compliant balloon versus predilation with a new scoring balloon. Am J Cardiol. 2007;100:812 7. 532. Baim DS, Wahr D, George B, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation. 2002;105:1285 90. 533. Coolong A, Baim DS, Kuntz RE, et al. Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients. Circulation. 2008;117:790 7. 534. Mauri L, Cox D, Hermiller J, et al. The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Levine et al 2011 ACCF/AHA/SCAI PCI Guideline e633 Embolic Protection System: a randomized, prospective, multicenter clinical trial. J Am Coll Cardiol. 2007;50:1442 9. 535. Stone GW, Rogers C, Hermiller J, et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation. 2003;108: 548 53. 536. Hoffmann R, Hamm C, Nienaber CA, et al. Implantation of sirolimus- eluting stents in saphenous vein grafts is associated with high clinical follow-up event rates compared with treatment of native vessels. Coron Artery Dis. 2007;18:559 64. 537. Kunadian B, Dunning J, Vijayalakshmi K, et al. Meta-analysis of ran- domized trials comparing anti-embolic devices with standard PCI for improving myocardial reperfusion in patients with acute myocar-dial infarction. Catheter Cardiovasc Interv. 2007;69:488 96. 538. Cohen M, Urban P, Christenson JT, et al. Intra-aortic balloon counter- pulsation in US and non-US centres: results of the Benchmark Registry. Eur Heart J. 2003;24:1763 70. 539. Stone GW, Ohman EM, Miller MF, et al. Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: the benchmark registry. J Am Coll Cardiol. 2003;41:1940 5. 540. Briguori C, Sarais C, Pagnotta P, et al. Elective versus provisional intra-aortic balloon pumping in high-risk percutaneous transluminal coronary angioplasty. Am Heart J. 2003;145:700 7. 541. Mishra S, Chu WW, Torguson R, et al. Role of prophylactic intra-aortic balloon pump in high-risk patients undergoing percutaneous coronary intervention. Am J Cardiol. 2006;98:608 12. 542. Perera D, Stables R, Thomas M, et al. Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention: a randomized controlled trial. JAMA. 2010;304:867 74. 543. Gupta A, Allaqaband S, Bajwa T. Combined use of Impella device and intra-aortic balloon pump to improve survival in a patient in profound cardiogenic shock post cardiac arrest. Catheter Cardiovasc Interv. 2009; 74:975 6. 544. Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008;52: 1584 8. 545. Henriques JP, Remmelink M, Baan J Jr, et al. Safety and feasibility of elective high-risk percutaneous coronary intervention procedures with left ventricular support of the Impella Recover LP 2.5. Am J Cardiol. 2006;97:990 2. 546. Remmelink M, Sjauw KD, Henriques JP, et al. Effects of mechanical left ventricular unloading by Impella on left ventricular dynamics in high-risk and primary percutaneous coronary intervention patients. Catheter Cardiovasc Interv. 2010;75:187 94. 547. Dixon SR, Henriques JP, Mauri L, et al. A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (The PROTECT I Trial): initial US experience. J Am Coll Cardiol Intv. 2009;2:91 6. 548. Sjauw KD, Konorza T, Erbel R, et al. Supported high-risk percutaneous coronary intervention with the Impella 2.5 device the Europella registry. J Am Coll Cardiol. 2009;54:2430 4. 549. PROTECT II (A Prospective, Multicenter, Randomized Controlled Trial of the IMPELLA RECOVER LP 2.5 System Versus Intra Aortic Balloon Pump in Patients Undergoing Non Emergent High Risk PCI) trial. Available at: http://clinicaltrials.gov/ct2/show/NCT00562016. Accessed August 16, 2011. 550. Kar B, Gregoric ID, Basra SS, et al. The percutaneous ventricular assist device in severe refractory cardiogenic shock. J Am Coll Cardiol. 2011;57:688 96. 551. Kar B, Adkins LE, Civitello AB, et al. Clinical experience with the TandemHeart percutaneous ventricular assist device. Tex Heart Inst J. 2006;33:111 5. 552. Singh IM, Holmes DR Jr, Rihal CS. Impact of tandem heart percutane- ous left ventricular assist device on invasive hemodynamics. i2 Oral Contributions. Presentation Number: 2904-10. J Am Coll Cardiol. 2010; 55:A180.E1684. Abstract. 553. Kovacic JC, Nguyen HT, Karajgikar R, et al. The Impella Recover 2.5 and TandemHeart ventricular assist devices are safe and associated with equivalent clinical outcomes in patients undergoing high-risk percuta- neous coronary intervention. Catheter Cardiovasc Interv. 2011: pub- lished online before print January 13, 2011, doi:10.1002/ccd.22929. 554. Vranckx P, Schultz CJ, Valgimigli M, et al. Assisted circulation using the TandemHeart during very high-risk PCI of the unprotected left main coronary artery in patients declined for CABG. Catheter Cardiovasc Interv. 2009;74:302 10. 555. Aragon J, Lee MS, Kar S, et al. Percutaneous left ventricular assist device: TandemHeart for high-risk coronary intervention. Catheter Cardiovasc Interv. 2005;65:346 52. 556. Rajdev S, Krishnan P, Irani A, et al. Clinical application of prophylactic percutaneous left ventricular assist device (TandemHeart) in high-risk percutaneous coronary intervention using an arterial pre-closure tech- nique: single-center experience. J Invasive Cardiol. 2008;20:67 72. 557. Green SM, Krauss B. Procedural sedation terminology: moving beyond conscious sedation. Ann Emerg Med. 2002;39:433 5. 558. American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology. 2002;96: 1004 17. 559. Joint Commission on Accreditation of Healthcare Organization. Com- prehensive Accreditation Manual: CAMH for Hospitals. Oak-brook Terrace, Il: Joint Commission Resources; 2010. 560. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary- artery stents. N Engl J Med. 1996;334:1084 9. 561. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71 86. 562. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for sec- ondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 Update. Circulation. 2006;113:2363 72. 563. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373: 1849 60. 564. Gurbel PA, Bliden KP, Zaman KA, et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation. 2005;111:1153 9. 565. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI- CLARITY study. JAMA. 2005;294:1224 32. 566. van der Heijden DJ, Westendorp IC, Riezebos RK, et al. Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation. J Am Coll Cardiol. 2004; 44:20 4. 567. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopi- dogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001 15. 568. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361: 1045 57. 569. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607 21. 570. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527 33. 571. Brar SS, Kim J, Brar SK, et al. Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. J Am Coll Cardiol. 2008;51:2220 7. 572. Steinhubl SR, Berger PB, Mann JTI, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411 20. 573. Patrono C, Baigent C, Hirsh J, et al. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133:199S 233S. 574. Steinhubl SR, Bhatt DL, Brennan DM, et al. Aspirin to prevent cardio- vascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med. 2009;150:379 86. 575. Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192 036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005;95:1218 22. 576. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108:1682 7. 577. von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intra- coronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation. 2005;112:2946 50. 578. Siller-Matula JM, Huber K, Christ G, et al. Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Heart. 2011;97:98 105. 579. Mangiacapra F, Muller O, Ntalianis A, et al. Comparison of 600 versus 300-mg clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol. 2010;106:1208 11. 580. Berger PB, Mahaffey KW, Meier SJ, et al. Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. Am Heart J. 2002;143:841 6. 581. Di Sciascio G, Patti G, Pasceri V, et al. Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYo- cardial Damage during Angioplasty) randomized trial. J Am Coll Cardiol. 2010;56:550 7. 582. Widimsky P, Motovska Z, Simek S, et al. Clopidogrel pre-treatment in stable angina: for all patients 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. Eur Heart J. 2008;29: 1495 503. 583. AstraZeneca. Brilinta REMS document. NDA 22-433. Reference ID: 2976456. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/UCM264004. pdf. [Package insert]. Accessed September 9, 2011. 584. Antoniucci D, Migliorini A, Parodi G, et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial com- paring infarct artery stenting plus abciximab with stenting alone. Circu- lation. 2004;109:1704 6. 585. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angio-graphic reste- nosis rate after the placement of coronary stents following acute myo- cardial infarction. J Am Coll Cardiol. 2000;35:915 21. 586. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957 66. 587. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glyco-protein IIb/IIIa inhibition with coronary stenting for acute myocar-dial infarction. N Engl J Med. 2001;344:1895 903. 588. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarc- tion: a meta-analysis of randomized trials. JAMA. 2005;293:1759 65. 589. Mehilli J, Kastrati A, Schulz S, et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percu- taneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation. 2009;119:1933 40. 590. De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J. 2009;30:2705 13. 591. Bellandi F, Maioli M, Gallopin M, et al. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Catheter Car- diovasc Interv. 2004;62:186 92. 592. Romagnoli E, Burzotta F, Trani C, et al. Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI. Int J Cardiol. 2005;105:250 5. 593. Iversen A, Galatius S, Jensen JS. The optimal route of administration of the glycoprotein IIb/IIIa receptor antagonist abciximab during percuta- neous coronary intervention; intravenous versus intracoronary. Curr Cardiol Rev. 2008;4:293 9. 594. Wohrle J, Nusser T, Mayer C, et al. Intracoronary application of abciximab in patients with ST-elevation myocardial infarction. EuroIn- tervention. 2008;3:465 9. 595. Kakkar AK, Moustapha A, Hanley HG, et al. Comparison of intra- coronary vs. intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv. 2004;61:31 4. 596. Wohrle J, Grebe OC, Nusser T, et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation. 2003;107:1840 3. 597. Bertrand OF, Rodes-Cabau J, Larose E, et al. Intracoronary compared to intravenous abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study. Am J Cardiol. 2010;105: 1520 7. 598. Deibele AJ, Kirtane AJ, Pinto DS, et al. Intracoronary bolus adminis- tration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina. J Thromb Throm- bolysis. 2006;22:47 50. 599. Yang XC, Zhang DP, Wang LF, et al. [Effects of intracoronary or intravenous tirofiban administration in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary inter- vention]. Zhonghua Xin Xue Guan Bing Za Zhi. 2007;35:517 22. 600. Deibele AJ, Jennings LK, Tcheng JE, et al. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary eptifibatide (ICE) Trial. Circulation. 2010;121:784 91. 601. Hansen PR, Iversen A, Abdulla J. Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis. J Invasive Cardiol. 2010;22: 278 82. 602. Galache Osuna JG, Sanchez-Rubio J, Calvo I, et al. [Does intracoro-nary abciximab improve the outcome of percutaneous coronary inter- ventions? A randomized controlled trial]. Rev Esp Cardiol. 2006;59: 567 74. 603. Wu TG, Zhao Q, Huang WG, et al. Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Circ J. 2008;72:1605 9. 604. Marciniak SJ Jr, Mascelli MA, Furman MI, et al. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost. 2002;87:1020 5. 605. Montalescot G, Borentain M, Payot L, et al. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2004;292:362 6. 606. Maioli M, Bellandi F, Leoncini M, et al. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). J Am Coll Cardiol. 2007;49:1517 24. 607. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarc- tion: quantitative review of randomised trials. Lancet. 2006;367: 579 88. 608. Van t Hof AWJ, ten Berg JM, Heestermans T, et al. Prehospital ini- tiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multi-centre, double- blind, randomised controlled trial. Lancet. 2008;372:537 46. 609. ten Berg JM, van t Hof AWJ, Dill T, et al. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome. J Am Coll Cardiol. 2010;55:2446 55. 610. Ellis SG, Tendera M, de Belder MA, et al. 1-year survival in a ran- domized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. J Am Coll Cardiol Intv. 2009;2:909 16. 611. Ellis SG, Tendera M, de Belder MA, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med. 2008;358: 2205 17. 612. El Khoury C, Dubien PY, Mercier C, et al. Prehospital high-dose tirofiban in patients undergoing primary percutaneous intervention. The AGIR-2 study. Arch Cardiovasc Dis. 2010;103:285 92. Levine et al 2011 ACCF/AHA/SCAI PCI Guideline e635 613. The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascu- larization. N Engl J Med. 1997;336:1689 96. 614. Boersma E, Akkerhuis KM, Theroux P, et al. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syn- dromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation. 1999; 100:2045 8. 615. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med. 1999;340:1623 9. 616. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary inter- vention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA. 2006;295:1531 8. 617. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment- elevation acute coronary syndromes. Circulation. 2001;104:2767 71. 618. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angio- plasty. The EPIC Investigation. N Engl J Med. 1994;330:956 61. 619. Valgimigli M, Percoco G, Barbieri D, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J Am Coll Cardiol. 2004;44:14 9. 620. EPISTENT Investigators. Randomised placebo-controlled and balloon- angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87 92. 621. ESPIRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo- controlled trial [published correction appears in Lancet. 2001;357:1370]. Lancet. 2000;356:2037 44. 622. Kastrati A, Mehilli J, Schuhlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med. 2004;350:232 8. 623. Mehilli J, Kastrati A, Schuhlen H, et al. 